Achieving Clinical Trials Transparency

Achieving Clinical Trials Transparency

Recent policy changes by Europe’s regulatory authority for drugs and devices has rekindled the pharmaceutical industry’s focus on clinical trials transparency. While there have been many initiatives to enhance openness in drug trials, the European Medicine Agency’s (EMA) requirement to make a trial’s clinical study report (CSR) publicly available is seen as a revolutionary move to boost public trust in the drug approvals process.

As the comprehensive report that details the protocol and results of a clinical trial, the CSR can contain highly sensitive health information about the study’s participants — placing the issue of patient privacy front and center. It also leaves many in the biopharmaceutical community wondering how to meet the EMA’s new transparency requirement while remaining compliant with privacy legislation and protecting their own confidential information.

How biopharmaceutical companies choose to anonymize their clinical trial data and reports have serious implications for transparency and their ability to leverage data for secondary uses. On the surface, different approaches to protecting the privacy of trial participants may appear to be equally sound, but they can have vastly different results when it comes to the usefulness of the anonymized content for subsequent analysis.

Understanding the drawbacks and benefits of the different methods for anonymization can help pharma companies better position themselves for the future. By aligning with best practice guidelines, they will not only be able to meet new transparency mandates but do so while complying with privacy regulations and maximizing the quality of data that can be shared for secondary purposes.

Make sure to download your copy of Achieving Clinical Trials Transparency today to learn how your organization can balance the demands and risks of data sharing.

Here are key highlights from April 2022 detailing global news and regulatory updates. US & Canada Canada’s privacy commissioner urges government to update federal…
Here are key highlights from March 2022 detailing global news and regulatory updates. US & Canada Canadian Bar Association identifies ways to improve the…
Previous
Next

Join the next 5 Safes Data Privacy webinar

This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.